Scott H Kaufmann
Overview
Explore the profile of Scott H Kaufmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
9347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steen T, Espinoza I, Duran C, Casadevall G, Serrano-Hervas E, Cuyas E, et al.
Neoplasia
. 2025 Feb;
62:101143.
PMID: 39999714
Resistance to mitochondrial apoptosis is a major driver of chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, pharmacological manipulation of the mitochondrial apoptosis threshold in PDAC cells remains an unmet therapeutic...
2.
Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implications
Thirsangu P, Jin L, Ray U, Zhao A, Wu X, Hou X, et al.
bioRxiv
. 2025 Jan;
PMID: 39868276
In our efforts to enhance sensitivity to PARP inhibitors, we identified clofarabine (CLF) as a potential therapy for drug-resistant ovarian cancer and nuclear trafficking of Cathepsin L (CTSL) as a...
3.
Caggiano R, Prokhorova E, Duma L, Schutzenhofer K, Lauro R, Catara G, et al.
Neoplasia
. 2024 Nov;
59:101092.
PMID: 39615107
The ADP-ribosyl hydrolases PARG and ARH3 counteract PARP enzymatic activity by removing ADP-ribosylation. PARG and ARH3 activities have a synthetic lethal effect; however, the specific molecular mechanisms underlying this response...
4.
Badar T, Knutson K, Knutson K, Foran J, Foran J, Gangat N, et al.
Blood Adv
. 2024 Nov;
9(2):239-243.
PMID: 39571168
No abstract available.
5.
Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A, et al.
Mol Cancer
. 2024 Oct;
23(1):224.
PMID: 39375715
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer...
6.
Csizmar C, Saliba A, Greipp P, Alkhateeb H, Begna K, Foran J, et al.
Haematologica
. 2024 Jun;
109(11):3785-3789.
PMID: 38899336
No abstract available.
7.
Rodman E, Emch M, Hou X, Bajaj A, Pearson N, John A, et al.
bioRxiv
. 2024 Jun;
PMID: 38895264
Statement Of Significance: Lestaurtinib is a novel inhibitor of ovarian cancer, including chemotherapy- and PARPi-resistant models, that acts through robust inhibition of the JAK/STAT pathway and synergizes with standard-of-care agents...
8.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
9.
Meagher N, White K, Wilkens L, Bandera E, Berchuck A, Carney M, et al.
Am J Epidemiol
. 2024 May;
193(9):1242-1252.
PMID: 38775277
Limited estimates exist on risk factors for epithelial ovarian cancer (EOC) in Asian, Hispanic, and Native Hawaiian/Pacific Islander women. Participants in this study included 1734 Asian (n = 785 case...
10.
Vincelette N, Yu X, Kuykendall A, Moon J, Su S, Cheng C, et al.
Blood Cancer Discov
. 2024 May;
5(4):276-297.
PMID: 38713018
Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients...